Biotrade Recommends Consumers Stop Consumption of U-Dream Product Immediately
VICTORIA, Dec. 20, 2019 /CNW/ - On December 17th, Health Canada formally indicated that they have found "Zopiclone impurity 22" in some batches of the U-Dream product. This is not the same as Zopiclone, a known pharmaceutical sleep aid (it is a similar molecule). Health Canada has confirmed that Zopiclone is not present in the product.
Biotrade Canada is in the process of conducting independent testing. As Health Canada has not given any indication regarding the amounts of the impurity detected, Biotrade recommends consumers stop using U-Dream products. More information can be found at www.udreamherbal.com or 250.733.2028.
As of November 21st, based on an initial concern raised by Health Canada, Biotrade Canada immediately stopped distribution and informed retailers to pull the product from store shelves and to stop selling.
In a bid to foster excellence and innovation in the healthcare industry, the esteemed Dr. Vidal Sheen proudly announces the launch of The Dr. Vidal Sheen Grant for Healthcare Students. With a robust focus on academic prowess, compassionate care, and...
Rexall is proud to unveil its first Pharmacist Care Walk-In Clinic in Barrie, Ontario on Friday, April 19. Located at 353 Duckworth Street, the clinic will offer personalized care to the community while providing immediate pharmacist treatment for...
Caring for communities extends beyond life-changing work in operating rooms and physician offices. Hartford HealthCare leadership today highlighted its corporate responsibility to environmental, social and economic sustainability in announcing its...
Concept Medical, a pioneer in innovative drug delivery technologies, proudly announces the commencement of its groundbreaking IDE clinical study, "MAGICAL-ISR" using MagicTouch ? Sirolimus drug coated balloon (DCB), for the management of in-stent...
The American College of Physicians (ACP) today released an update of its 2017 guideline with clinical recommendations for the use of newer pharmacological treatments of adults with Type 2 diabetes. The clinical guideline is based on the best...
Pieris Pharmaceuticals, Inc. today announced that its Board of Directors has approved a 1-for-80 reverse stock split of the Company's common stock, par value $0.001, which will be effective at 5:00 pm Eastern Time on April 22, 2024. The Company's...
